<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134952</url>
  </required_header>
  <id_info>
    <org_study_id>UWO12961</org_study_id>
    <nct_id>NCT01134952</nct_id>
  </id_info>
  <brief_title>Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)</brief_title>
  <official_title>A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>London Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different immunosuppressive drugs used in transplantation may reduce the body's defences
      against infection differently. It is known that patients with Hepatitis C virus, known as
      HCV, who switched from azathioprine to mycophenolate mofetil experienced an increase in viral
      load. Despite this, mycophenolate mofetil is used because it prevents rejection more reliably
      than azathioprine. Sirolimus is an another immunosuppressive agent that reliably prevents
      rejection and may have antiviral activity. This study is designed to see if the viral load of
      HCV and other viruses is reduced by switching from mycophenolate to sirolimus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) persistence after liver transplantation for HCV end-stage liver
      disease is universal and in this clinical setting, HCV mediated liver injury has been
      reported to follow a more progressive course compared to the non-immunosuppressed patient.
      Additionally, patients with recurrent chronic hepatitis C develop higher viral load compared
      to pre-transplant levels. Such persistently high viral burden post transplant may contribute
      to allograft damage. The choice of calcineurin inhibitor (CNI) does not effect recurrence
      rates of HCV hepatitis. HCV is also associated with renal dysfunction so that reduction in
      exposure to calcineurin inhibitors (CNI) is desirable. Unfortunately steroids are associated
      with a marked increase in HCV replication and cannot be used to reduce CNI doses.
      Mycophenolate mofetil (MMF) increases HCV viral load. A recent increase in the severity of
      recurrent hepatitis in patients with HCV receiving liver transplants has been attributed to
      MMF and interleukin-2 receptor blockers. Increased fibrosis of the liver occurs during
      antiviral anti HCV treatment in patients taking mycophenolate but patients on azathioprine
      develop cirrhosis faster, possibly because of rejection.

      A large industry sponsored phase III clinical trial has been underway for several years where
      patients have substituted sirolimus (SRL) for calcineurin inhibitors after liver
      transplantation. The object of that study is to determine impact of conversion on renal
      function. No detrimental effect (thrombosis, rejection or recurrent viral infection) was
      apparent to the safety board after two reviews. No study has compared SRL to MMF after liver
      transplantation.

      SRL, an immunosuppressive drug that inhibits the activation and proliferation of
      T-lymphocytes, is associated with reduction of Epstein Barr Virus (EBV) post-transplantation
      viral load in children. Experimentally it inhibits the growth of EBV B-cell lymphoma. A pilot
      study of tacrolimus with SRL showed a powerful anti-rejection effect but a subsequent trial
      was halted early because of an increase in hepatic artery thrombosis even though the rates of
      thrombosis in either arm of the study was below that expected. A recent large series in
      patients with hepatocellular carcinoma (most of whom had HCV) who received large doses of SRL
      showed a beneficial anti-cancer effect without thrombosis. The randomised trials and the
      reported series all had large numbers of patients with HCV. The absence of obvious recurrent
      HCV hepatitis and the low rates of cytomegalovirus (CMV) disease coupled with the known
      inhibition of EBV replication gives hope that SRL has anti-viral properties at
      immunosuppressive doses. Early reports confirm that hope: 1) successful liver transplantation
      in patients with HIV and HCV. &quot;Significantly better control of HIV and HCV replication was
      found among patients taking RAPA monotherapy (P=0.0001 and 0.03, respectively)&quot;; 2) switching
      to sirolimus in renal transplant recipients with hepatitis C virus: HCV replication reduced
      by switch to sirolimus; 3) sustained, spontaneous disappearance of serum HCV-RNA under
      immunosuppression after liver transplantation for HCV cirrhosis: two liver recipients who
      spontaneously cleared HCV after switch to sirolimus.

      SRL (2 mg/day) and MMF (2g/day) are licensed as adjuvant immunosuppressive agents to be used
      in kidney transplantation with cyclosporine so that immunosuppressive equivalent doses are
      1mg SRL = 1g MMF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta Hepatitis C Viral Load</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change in HCV load determined 3 months after switch from MMF to SRL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final Hepatitis C Viral Load</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change in HCV load determined 3 months after switch from SRL to MMF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sirolimus Trough Level</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Tacrolimus Trough Level</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change determined 3 months after switch from MMF to SRL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Bilirubin</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change determined 3 months after switch from MMF to SRL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Alkaline Phosphatase</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change determined 3 months after switch from MMF to SRL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Alanine Aminotransferase</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change determined 3 months after switch from MMF to SRL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Hemoglobin</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change determined 3 months after switch from MMF to SRL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Platelet Count</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change determined 3 months after switch from MMF to SRL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Cholesterol Fasting Level</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change determined 3 months after switch from MMF to SRL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Triglyceride Fasting Level</measure>
    <time_frame>3 month</time_frame>
    <description>Percent change determined 3 months after switch from MMF to SRL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Mycophenolate to sirolimus switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate to sirolimus switch</intervention_name>
    <description>Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.</description>
    <arm_group_label>Mycophenolate to sirolimus switch</arm_group_label>
    <other_name>rapamune</other_name>
    <other_name>rapamycin</other_name>
    <other_name>mycophenolic mofetil</other_name>
    <other_name>mycophenolic acid</other_name>
    <other_name>cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent HCV after liver transplantation

          -  Taking mycophenolate mofetil

          -  Stable liver function

        Exclusion Criteria:

          -  Pregnant females or couples unwilling to use contraception

          -  Intolerance or allergy to sirolimus

          -  Patients taking anti-HCV therapy

          -  Patients taking medications known to alter the levels of sirolimus

          -  History of thromboembolic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian McAlister, MB, FRCSC</last_name>
    <role>Study Director</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natasha Chandok, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://works.bepress.com/vivianmcalister/</url>
    <description>PI research website</description>
  </link>
  <link>
    <url>http://www.lhsc.on.ca/About_Us/MOTP/</url>
    <description>Transplant Program website</description>
  </link>
  <reference>
    <citation>Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 2004 Jan;10(1):52-7.</citation>
    <PMID>14755778</PMID>
  </reference>
  <reference>
    <citation>McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet. 2000 Jan 29;355(9201):376-7.</citation>
    <PMID>10665560</PMID>
  </reference>
  <reference>
    <citation>Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation. 2010 Mar 27;89(6):733-8. doi: 10.1097/TP.0b013e3181c7dcc0.</citation>
    <PMID>20048692</PMID>
  </reference>
  <reference>
    <citation>Gallego R, Henriquez F, Oliva E, Camacho R, Hernández R, Hortal L, Sablón N, Quintana B, Santana R, Gonzalez F, Palop L, Vega N. Switching to sirolimus in renal transplant recipients with hepatitis C virus: a safe option. Transplant Proc. 2009 Jul-Aug;41(6):2334-6. doi: 10.1016/j.transproceed.2009.06.064.</citation>
    <PMID>19715912</PMID>
  </reference>
  <reference>
    <citation>Samonakis DN, Cholongitas E, Triantos CK, Griffiths P, Dhillon AP, Thalheimer U, Patch DW, Burroughs AK. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol. 2005 Dec;43(6):1091-3. Epub 2005 Sep 15.</citation>
    <PMID>16239045</PMID>
  </reference>
  <reference>
    <citation>Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, Susca M, Strazzabosco M, Bellusci R, Iemmolo RM, Grazi G, Zauli D, Cavallari A, Bianchi FB. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl. 2002 Jan;8(1):10-20.</citation>
    <PMID>11799480</PMID>
  </reference>
  <reference>
    <citation>Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl. 2003 Nov;9(11):S58-62. Review.</citation>
    <PMID>14586897</PMID>
  </reference>
  <reference>
    <citation>Sindhi R, Webber S, Venkataramanan R, McGhee W, Phillips S, Smith A, Baird C, Iurlano K, Mazariegos G, Cooperstone B, Holt DW, Zeevi A, Fung JJ, Reyes J. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation. 2001 Sep 15;72(5):851-5.</citation>
    <PMID>11571449</PMID>
  </reference>
  <reference>
    <citation>Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003 Aug 1;63(15):4472-80.</citation>
    <PMID>12907620</PMID>
  </reference>
  <reference>
    <citation>Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 2004 Oct;10(10):1301-11.</citation>
    <PMID>15376305</PMID>
  </reference>
  <reference>
    <citation>Iacob S, Cicinnati VR, Hilgard P, Iacob RA, Gheorghe LS, Popescu I, Frilling A, Malago M, Gerken G, Broelsch CE, Beckebaum S. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation. 2007 Jul 15;84(1):56-63.</citation>
    <PMID>17627238</PMID>
  </reference>
  <reference>
    <citation>Kornberg A, Küpper B, Tannapfel A, Hommann M, Scheele J. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol. 2005 Jan;5(1):107-15.</citation>
    <PMID>15589468</PMID>
  </reference>
  <reference>
    <citation>Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005161. Review.</citation>
    <PMID>17054241</PMID>
  </reference>
  <reference>
    <citation>Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation. 2000 Mar 15;69(5):991-4.</citation>
    <PMID>10755563</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <results_first_submitted>December 15, 2014</results_first_submitted>
  <results_first_submitted_qc>January 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2015</results_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>London Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Vivian McAlister</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>sirolimus</keyword>
  <keyword>everolimus</keyword>
  <keyword>mycophenolic acid</keyword>
  <keyword>hepatitis C virus</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>viral load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MMF SRL Switch</title>
          <description>Liver transplant recipients with Hepatitis C virus taking sirolimus (SRL) instead of mycophenolate mofetil (MMF) for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MMF MRL Switch</title>
          <description>Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C viral load</title>
          <units>10^7 HCV IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tacrolimus trough level</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bilirubin</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline phosphatase</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.5" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase</title>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.3" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145.1" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet count</title>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.3" spread="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Delta Hepatitis C Viral Load</title>
        <description>Percent change in HCV load determined 3 months after switch from MMF to SRL.</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>Liver transplant recipients with HCV 3 months after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Hepatitis C Viral Load</title>
          <description>Percent change in HCV load determined 3 months after switch from MMF to SRL.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Hepatitis C Viral Load</title>
        <description>Percent change in HCV load determined 3 months after switch from SRL to MMF</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients switched for 3 months from mycophenolate mofetil to sirolimus and then back to mycophenolate mofetil</description>
          </group>
        </group_list>
        <measure>
          <title>Final Hepatitis C Viral Load</title>
          <description>Percent change in HCV load determined 3 months after switch from SRL to MMF</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47" spread="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sirolimus Trough Level</title>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Sirolimus Trough Level</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Tacrolimus Trough Level</title>
        <description>Percent change determined 3 months after switch from MMF to SRL</description>
        <time_frame>3 month</time_frame>
        <population>2 patients did not have tacrolimus levels recorded during both time periods and are excluded</population>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>Liver transplant recipients switched from mycophenolate mofetil to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Tacrolimus Trough Level</title>
          <description>Percent change determined 3 months after switch from MMF to SRL</description>
          <population>2 patients did not have tacrolimus levels recorded during both time periods and are excluded</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Bilirubin</title>
        <description>Percent change determined 3 months after switch from MMF to SRL</description>
        <time_frame>3 month</time_frame>
        <population>Levels available at correct time in only 7 patients</population>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients 3 months after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Bilirubin</title>
          <description>Percent change determined 3 months after switch from MMF to SRL</description>
          <population>Levels available at correct time in only 7 patients</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Alkaline Phosphatase</title>
        <description>Percent change determined 3 months after switch from MMF to SRL</description>
        <time_frame>3 month</time_frame>
        <population>Levels not available at appropriate times in 2 patients</population>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients 3 months after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Alkaline Phosphatase</title>
          <description>Percent change determined 3 months after switch from MMF to SRL</description>
          <population>Levels not available at appropriate times in 2 patients</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Alanine Aminotransferase</title>
        <description>Percent change determined 3 months after switch from MMF to SRL</description>
        <time_frame>3 month</time_frame>
        <population>Levels at appropriate time not available in 2 patients</population>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients 3 months after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Alanine Aminotransferase</title>
          <description>Percent change determined 3 months after switch from MMF to SRL</description>
          <population>Levels at appropriate time not available in 2 patients</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Hemoglobin</title>
        <description>Percent change determined 3 months after switch from MMF to SRL</description>
        <time_frame>3 month</time_frame>
        <population>Levels at appropriate times not available in 2 patients</population>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients 3 months after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Hemoglobin</title>
          <description>Percent change determined 3 months after switch from MMF to SRL</description>
          <population>Levels at appropriate times not available in 2 patients</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Platelet Count</title>
        <description>Percent change determined 3 months after switch from MMF to SRL</description>
        <time_frame>3 month</time_frame>
        <population>Levels not available on 2 patients at appropriate time</population>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients 3 months after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Platelet Count</title>
          <description>Percent change determined 3 months after switch from MMF to SRL</description>
          <population>Levels not available on 2 patients at appropriate time</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Cholesterol Fasting Level</title>
        <description>Percent change determined 3 months after switch from MMF to SRL</description>
        <time_frame>3 month</time_frame>
        <population>Levels not available for 2 patients</population>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients 3 months after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Cholesterol Fasting Level</title>
          <description>Percent change determined 3 months after switch from MMF to SRL</description>
          <population>Levels not available for 2 patients</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Triglyceride Fasting Level</title>
        <description>Percent change determined 3 months after switch from MMF to SRL</description>
        <time_frame>3 month</time_frame>
        <population>Levels at appropriate times not available on 2 patients</population>
        <group_list>
          <group group_id="O1">
            <title>MMF SRL Switch</title>
            <description>All patients 3 months after switch from mycophenolate to sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Triglyceride Fasting Level</title>
          <description>Percent change determined 3 months after switch from MMF to SRL</description>
          <population>Levels at appropriate times not available on 2 patients</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MMF SRL Switch</title>
          <description>All patients during 3 month period of switch from mycophenolate mofetil (MMF) to sirolimus and for 3 months after switch back to MMF</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Greater than expected baseline variation; technical problems with laboratory measurement of HCV (two different platforms used); and poor recruitment over a long period make the results difficult to interpret.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Vivian McAlister</name_or_title>
      <organization>LondonHSC</organization>
      <phone>5196632920</phone>
      <email>vmcalist@uwo.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

